Hepatitis A

Hepatitis A is an acute, self-limiting infectious disease of the liver caused by the Hepatitis A virus (HAV). It is primarily transmitted via the fecal-oral route. The infection typically presents as an acute illness characterized by constitutional symptoms, constitutional GI distress, and jaundice, resolving completely without progressing to chronic liver disease or causing permanent hepatic damage in the vast majority of cases.

Hepatitis A is caused by the Hepatitis A virus (HAV), an unenveloped, positive-sense, single-stranded RNA virus belonging to the Hepatovirus genus of the Picornaviridae family. Transmission occurs primarily through the ingestion of food or water contaminated with the feces of an infected person, or through direct close physical contact with an infectious individual.

Following ingestion, HAV penetrates the mucosal epithelium of the intestine, enters the portal circulation, and reaches the liver. Viral uptake into hepatocytes occurs via a specific cellular receptor (HAVCR1/TIM-1). Viral replication occurs exclusively in the cytoplasm of hepatocytes. HAV itself is not directly cytopathic. Instead, hepatocellular injury is mediated by the host’s cellular immune response. Infiltrating HLA-restricted, CD8+ T lymphocytes and natural killer (NK) cells target infected hepatocytes, leading to apoptosis and lobular necrosis. Bilirubin excretion is impaired due to canalicular injury, resulting in cholestasis and jaundice.

HAV has a worldwide distribution, with high endemicity in developing countries where sanitation and access to clean water are poor. In these regions, most children are infected asymptomatically before age 9, conferring lifelong immunity. In developed countries with robust sanitation, infection occurs primarily in adulthood, presenting as sporadic outbreaks among travelers, men who have sex with men (MSM), and persons who inject drugs (PWID).

• Travel to or residence in areas with high HAV endemicity
• Poor sanitation and lack of safe drinking water
• Living in close quarters with an infected individual
• Being a sexual contact of an infected person
• Men who have sex with men (MSM)
• Recreational drug use (injection and non-injection)

• Vitals: Low-grade fever, occasional mild bradycardia relative to body temperature.
• Inspection: Scleral icterus, generalized jaundice, and cutaneous excoriations from scratching.
• Palpation: Tender hepatomegaly, occasionally mild splenomegaly.
• Auscultation: Unremarkable abdominal bowel sounds.

• A. Clinical Assessment: Identification of risk factors, travel history, and classic acute hepatitis symptoms.
• B. Laboratory Testing: Serologic confirmation and liver chemistry profiling.
• C. Imaging Studies: Abdominal ultrasound to rule out biliary tract obstruction.
• D. Functional Tests: Prothrombin time (PT) and International Normalized Ratio (INR) to evaluate hepatic synthetic function.
• E. Biopsy Findings: Seldom indicated; shows lobular disarray, hepatocyte necrosis, ballooning degeneration, and portal mononuclear infiltration.
• F. Genetic Testing: Not indicated for diagnosis.
• G. Differential Diagnosis: Differentiation from other viral hepatitis forms, drug-induced hepatotoxicity, and biliary tree pathology.

Test Name: IgM anti-HAV
Type: Blood Test
Purpose: Confirms acute Hepatitis A infection.
Expected Findings: Positive / Reactive.
Interpretation: Establishes a definitive diagnosis of acute HAV infection; remains detectable for 3 to 6 months post-onset. Test Name: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)
Type: Blood Test
Purpose: Assess hepatocellular injury.
Expected Findings: Markedly elevated (often >1000 U/L), with ALT typically higher than AST.
Interpretation: Indicates acute, severe hepatocyte damage. Test Name: Total and Direct Bilirubin
Type: Blood Test
Purpose: Assess cholestatic and excretory function.
Expected Findings: Elevated.
Interpretation: Confirms hepatocellular or cholestatic jaundice. Test Name: Prothrombin Time (PT) / INR
Type: Blood Test
Purpose: Evaluate hepatic synthetic capacity.
Expected Findings: Typically normal; elevated in severe cases.
Interpretation: An INR $\ge$ 1.5 indicates severe hepatic impairment and impending acute liver failure.

Abdominal Ultrasound Purpose: To exclude mechanical biliary tract obstruction in patients presenting with jaundice.

• Typical Findings: Normal or mildly enlarged liver (hepatomegaly), gallbladder wall thickening, absence of biliary ductal dilation.


• Clinical Importance: Confirms that jaundice is hepatocellular rather than post-hepatic (obstructive) in origin.

• Acute Hepatitis B or C: Clinically identical; distinguished only by positive serologies (e.g., HBsAg, IgM anti-HBc, or HCV RNA).
• Acute Hepatitis E: Clinically similar; distinguished by IgM anti-HEV testing (particularly relevant in pregnant women or travelers).
• Drug-Induced Liver Injury (DILI): Differentiated by exposure history (e.g., acetaminophen) and negative viral serology.
• Acute Cholecystitis / Choledocholithiasis: Characterized by biliary colic and ultrasound evidence of gallstones or biliary tree dilation.

• Fulminant Hepatic Failure: Rapidly progressive liver failure with encephalopathy and coagulopathy (rare, <1% of cases).
• Cholestatic Hepatitis: Prolonged jaundice and pruritus lasting several months, which eventually resolves.
• Relapsing Hepatitis: Recurrence of symptoms and elevated liver enzymes weeks to months after initial recovery, followed by final resolution.

The prognosis for Hepatitis A is excellent. Over 99% of patients achieve complete clinical and biochemical recovery within 3 to 6 months. It does not progress to chronic hepatitis or cirrhosis. The case fatality rate is extremely low (<0.1% overall) but is higher in adults over 50 or patients with pre-existing chronic liver disease.

• Primary Prevention: Routine childhood vaccination (two-dose series administered at least 6 months apart); vaccination for high-risk adults (travelers, MSM, patients with chronic liver disease).
• Secondary Prevention: Post-exposure prophylaxis (PEP) utilizing the HAV vaccine or immune globulin within 14 days of exposure.

The following homeopathic remedies have been historically indicated for symptoms associated with Hepatitis A. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Advanced Liver Function & Fibrosis Analyzer

Comprehensive multi-metric clinical liver analyzer. Simultaneously evaluates AST, ALT, Platelets to compute De Ritis Ratio, APRI Score, and FIB-4 Index for fibrosis staging.